Loading interactive chart...
1DInterval:
Date Range
1 min
Advertisement
X4 Pharmaceuticals, Inc. (48Q.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Follow
As of 08:01AM CEST. Market open.
Mountain
Settings
- Simply Wall St.
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns
Key Insights Institutions' substantial holdings in X4 Pharmaceuticals implies that they have significant influence over...
- GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on April 1, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee
- Zacks Small Cap Research
XFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…
By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Business Update PDUFA Date of April 30, 2024 for Mavorixafor for the treatment of WHIM Syndrome In the fourth quarter of 2023, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) filed a New Drug Application (NDA) for mavorixafor for the treatment of patients 12 and older with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis)
Advertisement
Advertisement
Advertisement